Document Detail


Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study.
MedLine Citation:
PMID:  22774407     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the morning blood pressure surge (MBPS) in Chinese patients with mild to moderate essential hypertension treated with long-term administration of olmesartan, an angiotensin II receptor antagonist according to ambulatory blood pressure monitoring (ABPM).
MATERIALS AND METHODS: In a multi-center, prospective study, we investigated the long-term efficacy of olmesartan by ABPM in 18-75 years-old Chinese patients with mild to moderate hypertension (clinic diastolic blood pressure [DBP] 90-109 mm Hg and systolic blood pressure [SBP] < 180 mmHg). After a 1 week placebo runin, 87 patients were treated with olmesartan 20 mg once daily in the morning for 24 weeks. Ambulatory blood pressure monitoring was conducted at baseline and at the end of 24 weeks. At baseline, patients with an MBPS > or = 23 mmHg were classified as the MBPS group (n = 41), and all other patients were classified as the non-MBPS group (n = 46).
RESULTS: The mean systolic and diastolic blood pressures (SBP/DBP) over 24 hours were reduced from 141.78 +/- 12.8/91.17 +/- 7.34 to 128.35 +/- 15.86/83.58 +/- 9.53 mmHg (p < 0.01). The mean blood pressure in the final 6 hours of the dosing interval dropped from 135.75 +/- 5.84/87.29 +/- 4.80 mmHg to 122.98 +/- 6.46/80.49 +/- 4.31 mmHg (p < 0.01). The MBPS for SBP/ DBP were reduced from 35.68 +/- 8.85/29.77 +/- 17.19 mmHg to 28.62 +/- 15.08/19.08 +/- 11.01 mmHg in the MBPS group (p < 0.05). The reductions in MBPS after treament with olmesartan were significantly different between the two groups (p < 0.01).
CONCLUSIONS: Olmesartan effectively reduces blood pressure in patients with essential hypertension, and olmesartan especially reduces the MBPS in MBPS-prone patients.
Authors:
Yuan Jiao; Yuannan Ke; Ningling Sun; Jiguang Wang; Wude Deng; Junren Zhu; ;
Related Documents :
3113957 - Haemodynamic effects of metoprolol and intravenous nitroglycerin versus metoprolol alon...
19887187 - Beta(1)-integrin mediates pressure-stimulated phagocytosis.
22567187 - Non invasive continuous hemodynamic evaluation of cirrhotic patients after postural cha...
1071677 - Clinical trial of the beta-adrenoreceptor-blocking agent tolamolol with the use of 24 h...
12878997 - Direct effects of dobutamine on the coronary microcirculation: comparison with adenosin...
16518327 - The course of diabetic glomerulopathy in patients with type i diabetes: a 6-year follow...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  16     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-07-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  653-9     Citation Subset:  IM    
Affiliation:
Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel approach to study oxidative stress in thyroid diseases: a preliminary study.
Next Document:  Assesment of correlation between bispectral index and four common sedation scales used in mechanical...